SCHEMBL12601080

SCHEMBL12601080

COc1ccc(NC(=O)c2c(O)c(F)c(C)n(C)c2=O)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.47
KMT2A Q03164 9/20 0.46
MEN1 O00255 8/20 0.46
MAPT P10636 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
PABPC1 P11940 2/20 0.46
POLB P06746 1/20 0.45
PIK3CA P42336 1/20 0.45
MTOR P42345 1/20 0.45
NPC1 O15118 3/20 0.44
KDM4E B2RXH2 2/20 0.44
LMNA P02545 3/20 0.44
ALDH1A1 P00352 1/20 0.44
HTT P42858 1/20 0.44
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43
IGF1R P08069 1/20 0.43
MET P08581 1/20 0.43
KDR P35968 1/20 0.43
BUB1 O43683 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12601083 0.83 MCHR1 (0.40) RAB9AKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL1776499 0.82 NPC1 (0.42) RAB9AKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL1399895 0.82 KCNQ3 (0.49) RAB9AKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL1399907 0.75 NPC1 (0.65) RAB9AKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL15452401 0.75 RAB9A (0.53) RAB9AKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL1779249 0.74 NPC1 (0.46) RAB9AKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL10676511 0.73 NPC1 (0.45) RAB9AKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL1890355 0.73 AHR (0.49) RAB9AKMT2AMEN1SMN1; SMN2POLB
SCHEMBL12605345 0.72 NPC1 (0.43) RAB9AKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL3519638 0.72 KMT2A (0.47) RAB9AKMT2AMEN1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943638-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-17 US disclosed
US-7943638-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-17 US disclosed
US-20090111852-A1 Carboxamide Compound and Use of the Same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-04-30 US disclosed
US-20090111852-A1 Carboxamide Compound and Use of the Same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-04-30 US disclosed
WO-2007007903-A2 CARBOXAMIDE COMPOUND AND USE OF THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111852-A1 Carboxamide Compound and Use of the Same CBR3, H1-3, H1-0 RAB9A 1566/4885KMT2A 298/4885MEN1 1042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.